Clin2
NCT05785039Possibly a fitRecruiting

Study drug for advanced bladder and other solid cancers

Urinary System TumorSolid Tumor

Treatments studied

Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.

This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
76 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Be 18 to 75 years old, and expected to live at least 3 months
  • Have advanced or metastatic urothelial cancer (urinary system cancer) or another confirmed solid tumor after standard treatment failed/intolerable or isn’t available
  • Have at least one measurable tumor spot (not the prostate) that can be tracked on scans
  • Be well enough to do daily activities (ECOG 0 or 1) and any side effects from prior treatment must be mild (≤ grade 1)
  • Blood, heart, and organ tests must be acceptable (including heart pumping function with ejection fraction ≥50%)
  • Can provide tumor tissue from within the last 3 years (or, if not, you may still qualify after the research doctor reviews your case)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05965856Recruiting· Phase 2
Testing two antibody medicines for advanced bladder and other cancers

This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.

Shanghai, Shanghai Municipality
NCT05803018Recruiting· Phase 1/Phase 2
Study drug for advanced gynecologic cancer that stopped working

This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.

Shanghai, Shanghai Municipality
NCT06718621Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.

Shanghai, Shanghai Municipality
NCT06493864Recruiting· Phase 1
BL-B16D1 for advanced breast cancer and solid tumors

This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.

Shanghai, Shanghai Municipality
NCT06469008Recruiting· Phase 1
Study of BL-B16D1 for advanced head and neck cancer and other solid tumors

This study tests a new drug, BL-B16D1, for people with advanced head and neck cancer or other solid tumors that have not been helped by standard treatments. The goal is to see if the drug is safe and effective.

Shanghai, Shanghai Municipality
NCT05470348Recruiting· Phase 1
Test drug BL-B01D1 for advanced breast and other solid cancers

This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.

Guangzhou, Guangdong

Hear when a new Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.